Hemostemix Inc

OTC: HMTXF · Healthcare · Biotechnology

Canadian filerHQ Calgary, ABReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH 8DQ —GM —SS 58

v0.1 · 35/100 weight · pillars only

↑ workforce scale, disclosure history · ↓ Piotroski F, Altman-Z

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$3.4M

Employees

488

Market cap

$7.4M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2025

Net income-$3.4M-4.7M CAD2025

Operating income-$4.0M-5.6M CAD2025

Total assets$617.4k846.2k CAD2025

Liabilities$4.2M5.8M CAD2025

Equity-$3.6M-5.0M CAD2025

Revenue trend

FY2018 – FY2025 · USD

FY18

FY19

FY20

FY21

FY22

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Hemostemix Inc booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Nexalin Technology, Inc.34D Wellgistics Health, Inc.19D Vynleads, Inc.20D Curanex Pharmaceuticals Inc Common Stock——

Key facts

CEOThomas A. Smeenk

SectorHealthcare

IndustryBiotechnology

HeadquartersCalgary, AB

ExchangeOTC: HMTXF

Employees488

IPO date2016-01-07

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.